Company intelligence / Profile preview
Aurinia
Edmonton, Alberta, Canadaauriniapharma.com ↗
- Ownership
- Public · AUPH
- Development stage
- Other
01
Overview
Aurinia markets the first FDA-approved oral therapy for lupus nephritis (voclosporin/LUPKYNIS) and is advancing recombinant fusion protein AUR200 targeting BAFF and APRIL in autoimmune diseases (Phase 1). A preclinical synthetic peptide (AUR300) aimed at fibrotic and autoimmune conditions is also in development.
- Therapeutic areas
- ImmunologyRare Diseases
- Modalities
- Small moleculeRecombinant fusion proteinSynthetic peptide
- Industry
- Biotech
02
Drug pipeline
7 assets6 more assets in the full pipeline.
03
Partnerships
Otsuka Pharmaceutical EuropeRiptide Bioscience
04
Financials
- Market cap
- $2.2B
- Total revenue
- $283.1M
- Enterprise value
- $1.7B
Beyond the preview
Go deeper on Aurinia.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aurinia.